Immunotherapy for Metasta c RCC
Table 2. Ongoing Phase III Studies in Front-Line Advanced/
Metasta c RCC
Study
Primary
endpoint
Sample
size
Study name
(Clinical trial
iden fier) Start date/status
Atezolizumab ±
bevacizumab vs.
suni nib
PFS 305 (1:1) IMmo on150
(NCT01984242)
Jan 2014/
ongoing/
enrollment closed
Nivolumab +
ipilimumab vs.
suni nib
PFS, OS 1070 (1:1) CheckMate 214
(NCT02231749)
Oct 2014/
ongoing/
enrollment closed
Atezolizumab +
bevacizumab vs.
suni nib
PFS, OS 900 (1:1) IMmo on151
(NCT02420821)
May 2015/
ongoing
Avelumab +
axi nib vs.
suni nib
PFS 583 (1:1) JAVELIN
Renal 101
(NCT02684006)
March 2016/
ongoing
Pembrolizumab
+ axi nib vs.
suni nib
PFS, OS 840 (1:1) MK-3475-426/
KEYNOTE-426
(NCT02853331)
Sept 2016/
ongoing
Pembrolizumab
+ lenva nib
OR
everolimus +
lenva nib vs.
suni nib
PFS 735 (1:1:1) (NCT02811861) Oct 2016/
ongoing/
enrollment open
Atezolizumab vs.
placebo
DFS 664 IMmo on010
(NCT03024996)
Jan 2017/
ongoing/
enrollment open
Nephrectomy
± nivolumab in
localized RCC
RFS 766 PROSPER
(NCT03055013)
Feb 2017/
ongoing
Nivolumab +
ipilimumab vs.
suni nib
OS 306 (1:1) SUNNIFORECAST
(NCT03075423)
An cipated April
2017/enrollment
not yet open
Nivolumab +
caboza nib or
nivolumab +
ipilimumab vs. +
caboza nib vs.
suni nib
PFS 1014
(1:1:1)
CheckMate 9ER
(NCT03141177)
An cipated June
2017
Nivolumab +
ipilimumab vs.
placebo
DFS 800 CheckMate 914
(NCT03138512)
An cipated June/
July 2017
